{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:29:56Z","timestamp":1790072996306,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute myeloid leukemia (AML) patients display dismal prognosis due to high prevalence of refractory and relapsed disease resulting from chemoresistance. Treatment protocols, primarily based on the anchor drug Cytarabine, remained chiefly unchanged in the past 50 years with no standardized salvage regimens. Herein we aimed at exploring potential pre-clinical treatment strategies to surmount Cytarabine resistance in human AML cells. We established Cytarabine-resistant sublines derived from human leukemia K562 and Kasumi cells, and characterized the expression of Cytarabine-related genes using real-time PCR and Western blot analyses to uncover the mechanisms underlying their Cytarabine resistance. This was followed by growth inhibition assays and isobologram analyses testing the sublines\u2019 sensitivity to the clinically approved drugs hydroxyurea (HU) and azidothymidine (AZT), compared to their parental cells. All Cytarabine-resistant sublines lost deoxycytidine kinase (dCK) expression, rendering them refractory to Cytarabine. Loss of dCK function involved dCK gene deletions and\/or a novel frameshift mutation leading to dCK transcript degradation via nonsense-mediated decay. Cytarabine-resistant sublines displayed hypersensitivity to HU and AZT compared to parental cells; HU and AZT combinations exhibited a marked synergistic growth inhibition effect on leukemic cells, which was intensified upon acquisition of Cytarabine-resistance. In contrast, HU and AZT combination showed an antagonistic effect in non-malignant cells. Finally, HU and AZT synergism was demonstrated on peripheral blood specimens from AML patients. These findings identify a promising HU and AZT combination for the possible future treatment of relapsed and refractory AML, while sparing normal tissues from untoward toxicity.<\/jats:p>","DOI":"10.1038\/s41419-019-1626-x","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T10:04:09Z","timestamp":1558087449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine"],"prefix":"10.1038","volume":"10","author":[{"given":"May","family":"Levin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bluma","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6692-8221","authenticated-orcid":false,"given":"Yehuda G.","family":"Assaraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,17]]},"reference":[{"key":"1626_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0065-230X(08)60703-4","volume":"72","author":"S Grant","year":"1998","unstructured":"Grant, S. Ara-C: cellular and molecular pharmacology. Adv. Cancer Res. 72, 197\u2013233 (1998).","journal-title":"Adv. Cancer Res."},{"key":"1626_CR2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/jcm4040665","volume":"4","author":"N Ramos","year":"2015","unstructured":"Ramos, N., Mo, C., Karp, J. & Hourigan, C. Current approaches in the treatment of relapsed and refractory acute myeloid leukemia. J. Clin. Med. 4, 665\u2013695 (2015).","journal-title":"J. Clin. Med."},{"key":"1626_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.exphem.2009.04.002","volume":"37","author":"JL Shipley","year":"2009","unstructured":"Shipley, J. L. & Butera, J. N. Acute myelogenous leukemia. Exp. Hematol. 37, 649\u2013658 (2009).","journal-title":"Exp. Hematol."},{"key":"1626_CR4","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm.2415","volume":"17","author":"K Eppert","year":"2011","unstructured":"Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17, 1086\u20131093 (2011).","journal-title":"Nat. Med."},{"key":"1626_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10555-007-9044-4","volume":"26","author":"J Zhang","year":"2007","unstructured":"Zhang, J. et al. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev. 26, 85\u2013110 (2007).","journal-title":"Cancer Metastasis Rev."},{"key":"1626_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/jhg.2013.38","volume":"58","author":"SW Yee","year":"2013","unstructured":"Yee, S. W. et al. Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia. J. Hum. Genet. 58, 353\u2013361 (2013).","journal-title":"J. Hum. Genet."},{"key":"1626_CR7","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.1073\/pnas.0913900107","volume":"107","author":"G Toy","year":"2010","unstructured":"Toy, G. et al. Requirement for deoxycytidine kinase in T and B lymphocyte development. Proc. Natl Acad. Sci. USA 107, 5551\u20135556 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1626_CR8","first-page":"518","volume":"42","author":"DS Shewach","year":"1992","unstructured":"Shewach, D. S., Reynolds, K. K. & Hertel, L. Nucleotide specificity of human deoxycytidine kinase. Mol. Pharmacol. 42, 518\u2013524 (1992).","journal-title":"Mol. Pharmacol."},{"key":"1626_CR9","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.V46.5.791.791","volume":"46","author":"CN Coleman","year":"1975","unstructured":"Coleman, C. N., Stoller, R. G., Drake, J. C. & Chabner, B. A. Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. Blood 46, 791\u2013803 (1975).","journal-title":"Blood"},{"key":"1626_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.exphem.2014.09.007","volume":"43","author":"D Nowak","year":"2015","unstructured":"Nowak, D. et al. Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance. Exp. Hematol. 43, 32\u201343 (2015).","journal-title":"Exp. Hematol."},{"key":"1626_CR11","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.V96.4.1517","volume":"96","author":"MJ Veuger","year":"2000","unstructured":"Veuger, M. J., Honders, M. W., Landegent, J. E., Willemze, R. & Barge, R. M. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood 96, 1517\u20131524 (2000).","journal-title":"Blood"},{"key":"1626_CR12","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/leu.2010.88","volume":"24","author":"SK Rathe","year":"2010","unstructured":"Rathe, S. K. & Largaespada, D. A. Deoxycytidine kinase is downregulated in Ara-C-resistant acute myeloid leukemia murine cell lines. Leukemia 24, 1513\u20131515 (2010).","journal-title":"Leukemia"},{"key":"1626_CR13","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1158\/0008-5472.CAN-07-5528","volume":"68","author":"J Cai","year":"2008","unstructured":"Cai, J. et al. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res. 68, 2349\u20132357 (2008).","journal-title":"Cancer Res."},{"key":"1626_CR14","first-page":"1165","volume":"34","author":"JH Song","year":"2009","unstructured":"Song, J. H. et al. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells. Int. J. Oncol. 34, 1165\u20131171 (2009).","journal-title":"Int. J. Oncol."},{"key":"1626_CR15","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1182\/blood.V99.4.1373","volume":"99","author":"MJT Veuger","year":"2002","unstructured":"Veuger, M. J. T., Heemskerk, M. H. M., Honders, M. W., Willemze, R. & Barge, R. M. Y. Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells. Blood 99, 1373\u20131380 (2002).","journal-title":"Blood"},{"key":"1626_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/ejh.12711","volume":"97","author":"N Degwert","year":"2016","unstructured":"Degwert, N. et al. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia. Eur. J. Haematol. 97, 239\u2013244 (2016).","journal-title":"Eur. J. Haematol."},{"key":"1626_CR17","doi-asserted-by":"crossref","unstructured":"Bhise, N. S., Lamba, V. & Lamba, J. Microrna expression and drug-induced changes in gene expression correlate with Ara-C chemosensitivity in AML cell lines. Blood 124, 3623 (2014).","DOI":"10.1182\/blood.V124.21.3623.3623"},{"key":"1626_CR18","first-page":"139","volume":"20","author":"S Martin-Aragon","year":"2000","unstructured":"Martin-Aragon, S. et al. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs. Anticancer Res. 20, 139\u2013150 (2000).","journal-title":"Anticancer Res."},{"key":"1626_CR19","first-page":"5956","volume":"59","author":"E M\u00e5nsson","year":"1999","unstructured":"M\u00e5nsson, E., Spasokoukotskaja, T., S\u00e4llstr\u00f6m, J., Eriksson, S. & Albertioni, F. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line. Cancer Res. 59, 5956\u20135963 (1999).","journal-title":"Cancer Res."},{"key":"1626_CR20","first-page":"1005","volume":"7","author":"AP Stegmann","year":"1993","unstructured":"Stegmann, A. P., Honders, M. W., Kester, M. G., Landegent, J. E. & Willemze, R. Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2\u2019-deoxycytidine. Leukemia 7, 1005\u20131011 (1993).","journal-title":"Leukemia"},{"key":"1626_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.cca.2006.09.014","volume":"377","author":"S Kanno","year":"2007","unstructured":"Kanno, S. et al. Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells. Clin. Chim. Acta 377, 144\u2013149 (2007).","journal-title":"Clin. Chim. Acta"},{"key":"1626_CR22","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2217\/pgs.15.44","volume":"16","author":"A Abraham","year":"2015","unstructured":"Abraham, A. et al. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. Pharmacogenomics 16, 877\u2013890 (2015).","journal-title":"Pharmacogenomics"},{"key":"1626_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0006-2952(02)01484-3","volume":"65","author":"E M\u00e5nsson","year":"2003","unstructured":"M\u00e5nsson, E. et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem. Pharmacol. 65, 237\u2013247 (2003).","journal-title":"Biochem. Pharmacol."},{"key":"1626_CR24","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1080\/1042819031000099698","volume":"44","author":"K Lotfi","year":"2003","unstructured":"Lotfi, K., Juliusson, G. & Albertioni, F. Pharmacological basis for cladribine resistance. Leuk. Lymphoma 44, 1705\u20131712 (2003).","journal-title":"Leuk. Lymphoma"},{"key":"1626_CR25","doi-asserted-by":"crossref","unstructured":"Quessar, A. M. et al. Hydroxyurea in the early management of acute myeloid leukemia and hyperleukocytosis. Blood 110, 4368 (2007).","DOI":"10.1182\/blood.V110.11.4368.4368"},{"key":"1626_CR26","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1182\/blood-2003-01-0135","volume":"101","author":"G Finazzi","year":"2003","unstructured":"Finazzi, G., Ruggeri, M., Rodeghiero, F. & Barbui, T. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood 101, 3749\u20133749 (2003).","journal-title":"Blood"},{"key":"1626_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/asheducation-2009.1.62","volume":"2009","author":"RE Ware","year":"2009","unstructured":"Ware, R. E. & Aygun, B. Advances in the use of hydroxyurea. Hematology 2009, 62\u201369 (2009).","journal-title":"Hematology"},{"key":"1626_CR28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2165\/00003088-199834050-00002","volume":"34","author":"PR Gwilt","year":"1998","unstructured":"Gwilt, P. R. & Tracewell, W. G. Pharmacokinetics and Pharmacodynamics of Hydroxyurea. Clin. Pharmacokinet. 34, 347\u2013358 (1998).","journal-title":"Clin. Pharmacokinet."},{"key":"1626_CR29","first-page":"2688","volume":"43","author":"F Rauscher","year":"1983","unstructured":"Rauscher, F. & Cadman, E. Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity. Cancer Res. 43, 2688\u20132693 (1983).","journal-title":"Cancer Res."},{"key":"1626_CR30","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/blood.V78.11.2937.2937","volume":"78","author":"K Bhalla","year":"1991","unstructured":"Bhalla, K., Swerdlow, P. & Grant, S. Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells. Blood 78, 2937\u20132944 (1991).","journal-title":"Blood"},{"key":"1626_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/10428190400007565","volume":"46","author":"L Larizza","year":"2005","unstructured":"Larizza, L., Magnani, I. & Beghini, A. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk. Lymphoma 46, 247\u2013255 (2005).","journal-title":"Leuk. Lymphoma"},{"key":"1626_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.149","volume":"3","author":"J Foucquier","year":"2015","unstructured":"Foucquier, J. & Guedj, M. Analysis of drug combinations: current methodological landscape. Pharmacol. Res. Perspect. 3, e00149 (2015).","journal-title":"Pharmacol. Res. Perspect."},{"key":"1626_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1096\/fj.08-113902","volume":"23","author":"E Errasti-Murugarren","year":"2009","unstructured":"Errasti-Murugarren, E., Molina-Arcas, M., Casado, F. J. & Pastor-Anglada, M. A splice variant of the SLC28A3 gene encodes a novel human concentrative nucleoside transporter-3 (hCNT3) protein localized in the endoplasmic reticulum. FASEB J. 23, 172\u2013182 (2009).","journal-title":"FASEB J."},{"key":"1626_CR34","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/leu.2016.314","volume":"31","author":"D Malani","year":"2017","unstructured":"Malani, D. et al. Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. Leukemia 31, 1187\u20131195 (2017).","journal-title":"Leukemia"},{"key":"1626_CR35","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S0968-0004(98)01208-0","volume":"23","author":"E Nagy","year":"1998","unstructured":"Nagy, E. & Maquat, L. E. A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance. Trends Biochem. Sci. 23, 198\u2013199 (1998).","journal-title":"Trends Biochem. Sci."},{"key":"1626_CR36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0021-9258(18)62546-3","volume":"246","author":"TG Obrig","year":"1971","unstructured":"Obrig, T. G., Culp, W. J., McKeehan, W. L. & Hardesty, B. The mechanism by which cycloheximide and related glutarimide antibiotics inhibit peptide synthesis on reticulocyte ribosomes. J. Biol. Chem. 246, 174\u2013181 (1971).","journal-title":"J. Biol. Chem."},{"key":"1626_CR37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nchembio.304","volume":"6","author":"T Schneider-Poetsch","year":"2010","unstructured":"Schneider-Poetsch, T. et al. Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nat. Chem. Biol. 6, 209\u2013217 (2010).","journal-title":"Nat. Chem. Biol."},{"key":"1626_CR38","doi-asserted-by":"publisher","first-page":"28995","DOI":"10.1074\/jbc.270.48.28995","volume":"270","author":"MS Carter","year":"1995","unstructured":"Carter, M. S. et al. A regulatory mechanism that detects premature nonsense codons in T-cell receptor transcripts in vivo is reversed by protein synthesis inhibitors in vitro. J. Biol. Chem. 270, 28995\u201329003 (1995).","journal-title":"J. Biol. Chem."},{"key":"1626_CR39","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s00277-003-0693-2","volume":"82","author":"MC Petti","year":"2003","unstructured":"Petti, M. C. et al. High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias. Ann. Hematol. 82, 476\u2013480 (2003).","journal-title":"Ann. Hematol."},{"key":"1626_CR40","doi-asserted-by":"publisher","first-page":"28599","DOI":"10.1074\/jbc.M111.256297","volume":"286","author":"M-R Pan","year":"2011","unstructured":"Pan, M.-R., Peng, G., Hung, W.-C. & Lin, S.-Y. Monoubiquitination of H2AX protein regulates DNA damage response signaling. J. Biol. Chem. 286, 28599\u201328607 (2011).","journal-title":"J. Biol. Chem."},{"key":"1626_CR41","doi-asserted-by":"publisher","first-page":"30806","DOI":"10.1074\/jbc.M111.257469","volume":"286","author":"C-Y Wu","year":"2011","unstructured":"Wu, C.-Y. et al. Critical role of monoubiquitination of histone H2AX protein in histone H2AX phosphorylation and DNA damage response. J. Biol. Chem. 286, 30806\u201330815 (2011).","journal-title":"J. Biol. Chem."},{"key":"1626_CR42","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1600-0609.1994.tb00098.x","volume":"52","author":"P Tosi","year":"1994","unstructured":"Tosi, P., Visani, G., Ottaviani, E., Tura, S. & Darnowski, J. W. Hydroxyurea enhances 3\u2019-azido-3\u2019-deoxythymidine (AZT) cytotoxicity in human chronic myeloid leukemia models. Eur. J. Haematol. 52, 291\u2013295 (1994).","journal-title":"Eur. J. Haematol."},{"key":"1626_CR43","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/j.1432-1033.1989.tb15261.x","volume":"186","author":"A Karlsson","year":"1989","unstructured":"Karlsson, A., Reichard, P. & Eckstein, F. Hydroxyurea increases the phosphorylation of 3\u2019-fluorothymidine and 3\u2019-azidothymidine in CEM cells. Eur. J. Biochem. 186, 689\u2013694 (1989).","journal-title":"Eur. J. Biochem."},{"key":"1626_CR44","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","volume":"21","author":"CF Thorn","year":"2011","unstructured":"Thorn, C. F. et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet. Genomics 21, 440\u2013446 (2011).","journal-title":"Pharmacogenet. Genomics"},{"key":"1626_CR45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drup.2015.11.004","volume":"24","author":"B Zhitomirsky","year":"2016","unstructured":"Zhitomirsky, B. & Assaraf, Y. G. Lysosomes as mediators of drug resistance in cancer. Drug Resist. Updat. 24, 23\u201333 (2016).","journal-title":"Drug Resist. Updat."},{"key":"1626_CR46","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.drup.2016.07.001","volume":"28","author":"RH Wijdeven","year":"2016","unstructured":"Wijdeven, R. H., Pang, B., Assaraf, Y. G. & Neefjes, J. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics. Drug Resist. Updat. 28, 65\u201381 (2016).","journal-title":"Drug Resist. Updat."},{"key":"1626_CR47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.drup.2017.05.002","volume":"31","author":"M Bar-Zeev","year":"2017","unstructured":"Bar-Zeev, M., Livney, Y. D. & Assaraf, Y. G. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance. Drug Resist. Updat. 31, 15\u201330 (2017).","journal-title":"Drug Resist. Updat."},{"key":"1626_CR48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.drup.2018.01.002","volume":"36","author":"RN Gacche","year":"2018","unstructured":"Gacche, R. N. & Assaraf, Y. G. Redundant angiogenic signaling and tumor drug resistance. Drug Resist. Updat. 36, 47\u201376 (2018).","journal-title":"Drug Resist. Updat."},{"key":"1626_CR49","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.drup.2012.07.002","volume":"15","author":"N Gonen","year":"2012","unstructured":"Gonen, N. & Assaraf, Y. G. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist. Updat. 15, 183\u2013210 (2012).","journal-title":"Drug Resist. Updat."},{"key":"1626_CR50","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev-cancerbio-042016-073434","volume":"1","author":"RL Beijersbergen","year":"2017","unstructured":"Beijersbergen, R. L., Wessels, L. F. A. & Bernards, R. Synthetic lethality in cancer therapeutics. Annu. Rev. Cancer Biol. 1, 141\u2013161 (2017).","journal-title":"Annu. Rev. Cancer Biol."},{"key":"1626_CR51","doi-asserted-by":"publisher","first-page":"8333","DOI":"10.1073\/pnas.83.21.8333","volume":"83","author":"PA Furman","year":"1986","unstructured":"Furman, P. A. et al. Phosphorylation of 3\u2019-azido-3\u2019-deoxythymidine and selective interaction of the 5\u2019-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl Acad. Sci. USA 83, 8333\u20138337 (1986).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1626_CR52","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm0897-922","volume":"3","author":"A Lavie","year":"1997","unstructured":"Lavie, A. et al. The bottleneck in AZT activation. Nat. Med. 3, 922\u2013924 (1997).","journal-title":"Nat. Med."},{"key":"1626_CR53","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2174\/1389203013380991","volume":"2","author":"RD Ladner","year":"2001","unstructured":"Ladner, R. D. The role of dUTPase and uracil-DNA repair in cancer chemotherapy. Curr. Protein Pept. Sci. 2, 361\u2013370 (2001).","journal-title":"Curr. Protein Pept. Sci."},{"key":"1626_CR54","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ccr.2012.04.038","volume":"22","author":"C-M Hu","year":"2012","unstructured":"Hu, C.-M. et al. Tumor cells require thymidylate kinase to prevent dUTP incorporation during DNA repair. Cancer Cell 22, 36\u201350 (2012).","journal-title":"Cancer Cell"},{"key":"1626_CR55","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1128\/AAC.41.2.460","volume":"41","author":"S Palmer","year":"1997","unstructured":"Palmer, S. & Cox, S. Increased activation of the combination of 3\u2019-azido-3\u2019-deoxythymidine and 2\u2019-deoxy-3\u2019-thiacytidine in the presence of hydroxyurea. Antimicrob. Agents Chemother. 41, 460\u2013464 (1997).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1626_CR56","doi-asserted-by":"crossref","unstructured":"Hayun, M. et al. Clonal selection in acute myeloid leukemia following intensive induction correlates with differences in differentiation capacity of leukemic sub-clones. Blood 128, 1697 (2016).","DOI":"10.1182\/blood.V128.22.1697.1697"},{"key":"1626_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02858-0","volume":"9","author":"TN Wong","year":"2018","unstructured":"Wong, T. N. et al. Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nat. Commun. 9, 455 (2018).","journal-title":"Nat. Commun."},{"key":"1626_CR58","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3892\/or.2015.3959","volume":"34","author":"JH SONG","year":"2015","unstructured":"SONG, J. H. et al. Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy. Oncol. Rep. 34, 488\u2013494 (2015).","journal-title":"Oncol. Rep."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1626-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1626-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1626-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T17:03:39Z","timestamp":1671210219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1626-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,17]]},"references-count":58,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["1626"],"URL":"https:\/\/doi.org\/10.1038\/s41419-019-1626-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,17]]},"assertion":[{"value":"7 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"390"}}